Improving Healthcare Delivery in Immuno-Oncology: A Global Quality Improvement Initiative-Module 2

Title:

Improving Healthcare Delivery in Immuno-Oncology: A Global Quality Improvement Initiative-Module 2

Topic: Oncology
Relevant Terms: Immunotherapy, Quality Improvement
Primary Audience: Physicians, physician assistants, nurse practitioners, registered nurses, and other healthcare providers
Launch Date: 21-Aug-18
Credits: 0.75 AMA PRA Category 1 Credit
Expiration Date: 21-Aug-19
Curriculum Name: A Global Quality Improvement Initiative in Immuno-Oncology

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Develop optimum treatment strategies using checkpoint inhibitors to treat a variety of tumor types
  2. Create approaches to monitor and manage immune-related adverse events (irAEs) resulting from treatment with immune checkpoint inhibitors
  3. Discuss best practices related to shared decision making in clinical practice
  4. Describe foundational principles of quality improvement as they relate to healthcare

    Faculty

    Joseph Jacobson, MD
    Chief Quality Officer
    Dana-Farber Cancer Institute
    Boston, Massachusetts, United State
    Timothy Gilligan, MD
    Vice-Chair for Education
    Cleveland Clinic Taussig Cancer Institute
    Cleveland, Ohio, United States
    John B Haanen, MD, PhD
    Molecular Oncology & Immunology Group Leader
    Netherlands Cancer institute
    Amsterdam, the Netherlands
    PROVIDER
    This activity is provided by prIME Oncology.

     
    CONTINUING MEDICAL EDUCATION
    prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.



    prIME Oncology designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    SUNSHINE ACT/EFPIA
    prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements. 
     
    SUPPORT
    This activity is supported by educational grants from Bristol-Myers Squibb, EMD Serono, and Pfizer.
     
    DISCLOSURES
    prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
     
    The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity.
     
    Dr Gilligan has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
    Dr Haanen has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
    Dr Jacobson has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
     
    The employees of prIME Oncology have disclosed:
    • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
    • Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
    • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
     
    DISCLOSURE REGARDING UNLABELED USE
    This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
     
    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.